A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.

Background: Several cancer therapies can prolong cardiac repolarization. This study assessed the potential of eribulin to affect cardiac repolarization in patients with advanced solid tumors.

Methods: In this Phase I, open-label, single-arm study, patients received eribulin mesylate (1.